Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Esperion Theraptc (NQ: ESPR )

2.135 +0.045 (+2.15%)
Streaming Delayed Price Updated: 11:07 AM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Esperion Theraptc

< Previous 1 2 3 4 5 6 7 8 Next >
The Latest Analyst Ratings for Esperion Therapeutics
Via Benzinga
Looking Into Esperion Therapeutics's Return On Capital Employed
Via Benzinga
Esperion Therapeutics's Earnings Outlook
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
Via Benzinga
Recap: Esperion Therapeutics Q3 Earnings
Esperion Therapeutics (NASDAQ:ESPR) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Esperion Therapeutics: Q2 Earnings Insights
Esperion Therapeutics (NASDAQ:ESPR) reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Esperion Therapeutics: Q1 Earnings Insights
Esperion Therapeutics (NASDAQ:ESPR) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Top Picks For 2023: Esperion
Esperion is a de-risked biotech company in the cardiovascular sector with its lead drug, bempedoic acid, already FDA approved to reduce LDL cholesterol. Let's take a closer look at why it's a top pick... 
Via Talk Markets
Esperion Therapeutics Reports Sooner Than Expected Positive Data From Nexletol Trial
Via Benzinga
Esperion Therapeutics's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q3, Esperion Therapeutics's (NASDAQ:ESPR) reported sales totaled $18.98 million. Despite a 16.9% increase in earnings, the company posted a loss of $55.12... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022
  
Via Benzinga
Earnings Scheduled For February 22, 2022
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report quarterly earnings at $0.13 per share on revenue of $439.63 million. • Sohu... 
Via Benzinga
U.S. Stock Futures Gain Ahead of Services PMI; Crude Oil Drops Over 1%
Pre-open movers 
Via Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Kiromic BioPharma (NASDAQ:KRBP) stock increased by 12.6% to $0.58 during Friday's after-market session. The market value of their outstanding shares is at $8.9 million. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2022
Upgrades 
Via Benzinga
A Peek Into The Markets: US Stock Futures Down Following Wednesday's Surge
Pre-open movers 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Esperion Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know
Esperion Therapeutics (NASDAQ:ESPR) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. How to Attend Esperion Therapeutics (ESPR) Conference Call Follow... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Sigilon Therapeutics (NASDAQ:SGTX) stock rose 15.5% to $1.49 during Monday's after-market session. The market value of their outstanding shares is at $48.1 million. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2022
Upgrades For Alpha Metallurgical Resources Inc (NYSE:AMR), B. Riley Securities upgraded the previous rating of Neutral to Buy. For the fourth quarter, Alpha Metallurgical... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Ocugen (NASDAQ:OCGN) stock rose 25.0% to $4.33 during Tuesday's regular session. As of 12:30 EST, Ocugen's stock is trading at a volume of 42.0 million,... 
Via Benzinga
Recap: Esperion Therapeutics Q4 Earnings
Esperion Therapeutics (NASDAQ:ESPR) reported its Q4 earnings results on Tuesday, February 22, 2022 at 07:00 AM. Here's what investors need to know about the... 
Via Benzinga
73 Biggest Movers From Yesterday
Gainers Imperial Petroleum Inc. (NASDAQ: IMPP) jumped 63.1% to close at $0.80 on Tuesday after declining around 7% on Friday. Indonesia Energy Corporation Limited (NYSE... 
Via Benzinga
50 Stocks Moving In Tuesday's Mid-Day Session
Gainers Indonesia Energy Corporation Limited (NYSE: INDO) jumped 75.2% to $7.87. Imperial Petroleum Inc. (NASDAQ: IMPP) rose 52.9% to $0.7500 after declining around 7% on Friday... 
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
On Monday, 71 stocks hit new 52-week lows. Noteable 52-Week Lows: 3M (NYSE:MMM) was the biggest company in terms of market cap to set a new 52-week low. OceanPal (... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Before 10 am on Friday, 110 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: Humana (NYSE:HUM) was the biggest company on a market cap... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.